GGrantIndex
← Leaderboards

Lynn Bry

Brigham And Women'S Hospital

$10,918,358
Attributed
$11,882,662
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,882,662 · 10

By mechanism

R01$7,882,753 · 4
P30$2,993,529 · 3
K08$503,280 · 1
R21$324,100 · 1
R03$179,000 · 1

Top collaborators

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Resources

Research focus

ResourcesComplexIn VivoPathogenResearch PersonnelGnotobioticTissuesProductionEpithelialMicrobiotaMemberFermentationMetabolicMolecularIn VitroGerm-FreeInfectionToxinNutrientGrowthLaboratoriesSourceAffectArea

Grant awards (34)

Harnessing commensal redox metabolism in infection prevention$849,858
R01 · FY2025 · AI · contact PI
Commensal control of C. difficile virulence$603,478
R01 · FY2025 · AI · contact PI
Harnessing commensal redox metabolism in infection prevention$841,796
R01 · FY2024 · AI · contact PI
Commensal control of C. difficile virulence$673,670
R01 · FY2024 · AI · contact PI
NMR-resolved dynamics of C. difficile metabolism$89,500
R03 · FY2024 · AI · contact PI
Commensal control of C. difficile virulence$673,670
R01 · FY2023 · AI · contact PI
NMR-resolved dynamics of C. difficile metabolism$89,500
R03 · FY2023 · AI · contact PI
Commensal control of C. difficile virulence$673,670
R01 · FY2022 · AI · contact PI
Gnotobiotics, Microbiology and Metagenomics Core$277,496
P30 · FY2022 · DK · contact PI
Commensal control of C. difficile virulence$748,420
R01 · FY2021 · AI · contact PI
Gnotobiotics, Microbiology and Metagenomics Core$315,996
P30 · FY2021 · DK · contact PI
Gnotobiotic, Microbiology and Metagenonomics$343,706
P30 · FY2020 · DK · contact PI
Gnotobiotic, Microbiology and Metagenonomics$308,458
P30 · FY2019 · DK · contact PI
Gnotobiotic, Microbiology and Metagenonomics$345,176
P30 · FY2018 · DK · contact PI
Gnotobiotic, Microbiology and Metagenonomics$342,412
P30 · FY2017 · DK · contact PI
Gnotobiotic, Microbiology and Metagenonomics$344,143
P30 · FY2016 · DK · contact PI
GNOTOBIOTICS AND MICROBIOLOGY CORE$156,299
P30 · FY2015 · DK · contact PI
GNOTOBIOTICS AND MICROBIOLOGY CORE$216,326
P30 · FY2014 · DK · contact PI
Epithelial Glycoconjugates as Barriers against Enteric Infections$373,283
R01 · FY2013 · HD
GNOTOBIOTICS AND MICROBIOLOGY CORE$164,559
P30 · FY2013 · DK · contact PI
Epithelial Glycoconjugates as Barriers against Enteric Infections$411,044
R01 · FY2012 · HD
GNOTOBIOTICS AND MICROBIOLOGY CORE$178,958
P30 · FY2012 · DK · contact PI
Epithelial Glycoconjugates as Barriers against Enteric Infections$412,584
R01 · FY2011 · HD
Epithelial Glycoconjugates as Barriers against Enteric Infections$33,051
R01 · FY2011 · HD
Crimson - i2b2 integration for high-throughput, scalable sample collection$445,000
R01 · FY2010 · LM · contact PI
Epithelial Glycoconjugates as Barriers against Enteric Infections$349,296
R01 · FY2010 · HD
Crimson - i2b2 integration for high-throughput, scalable sample collection$444,583
R01 · FY2009 · LM · contact PI
Epithelial Glycoconjugates as Barriers against Enteric Infections$349,350
R01 · FY2009 · HD
Role of T cells in self-limited mucosal infections$128,520
K08 · FY2006 · AI · contact PI
Protective role of cross-reactive anti-enteric antibody$162,050
R21 · FY2005 · AI
Role of T cells in self-limited mucosal infections$128,520
K08 · FY2005 · AI
Protective role of cross-reactive anti-enteric antibody$162,050
R21 · FY2004 · AI
Role of T cells in self-limited mucosal infections$128,520
K08 · FY2004 · AI
Role of T cells in self-limited mucosal infections$117,720
K08 · FY2003 · AI